Since its outbreak, Covid-19 has been responsible for more than 6 000 000 deaths. 1 Cancer is one of the most important risk factors for severe disease and death; hematological malignancies (HMs), specifically, have been associated with an estimated mortality rate of 37%. 2At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy to reduce the incidence and severity of Covid-19.Here, we present the results of a prospective, cohort study aimed to evaluate the humoral and cell-mediated immune response and the clinical efficacy of anti-SARS-CoV-2 vaccination in adult patients with HMs.The study included consecutive adult patients with HMs who had completed the first cycle of anti-SARS-CoV-2 vaccination. At enrollment, information was collected regarding patient demographics, HM characteristics, last HM therapy, anti-SARS-CoV-2 vaccination, and previous Covid-19. Active disease was defined as being

No abstract

One hundred and fifty-six German, Italian and Polish patients with confirmed aspirin-induced asthma underwent open oral challenges with increasing doses of tartrazine up to 25 mg. All positive challenges were repeated under double-blind conditions. Only 4 of 156 patients (all Polish) had positive reactions in a double-blind test, as evidenced by a fall in FEV₁ > 25% from baseline and corresponding clinical symptoms. Sixty-five patients who tolerated 25 mg tartrazine well received 50–3,000 mg tartrazine and none showed adverse reactions. Thus, intolerance to tartrazine appears to be rare among Central-European and South-European patients with aspirin-induced asthma, its frequency amounting to about 2.6%.